drugset / Trial / NCT00220727

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

NCT00220727 ↗

Phase 2 Completed 8 enrolled Grifols Therapeutics LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatograph Purified (IGIV-C) is similar when infused at two different infusion rates.

Timeline

Start
2003-07
Primary completion
2003-10
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified Unknown 1 g/kg Intravenous